Are you Dr. Stevens?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 110 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
3991 Dutchmans Ln
Suite 405
Louisville, KY 40207Phone+1 502-899-3366Fax+1 502-899-3455
Summary
- Dr. Don Stevens, MD is an oncologist in Louisville, Kentucky. He is currently licensed to practice medicine in Kentucky, Indiana, and Maryland. He is affiliated with Norton Womens and Childrens Hospital, UofL Health - UofL Hospital, and Norton Children's Hospital.
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1986 - 1988
University of Louisville School of MedicineResidency, Internal Medicine, 1983 - 1986- University of Louisville School of MedicineInternship, Transitional Year, 1982 - 1983
- University of Louisville School of MedicineResidency, Internal Medicine, 1982 - 1982
- University of Louisville School of MedicineClass of 1982
Certifications & Licensure
IN State Medical License 1991 - 2025
KY State Medical License 1983 - 2025
MD State Medical License 1986 - 1989- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- Top MD Consumers Checkbook
Clinical Trials
- Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma Start of enrollment: 2010 May 01
- Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Feb 04
- A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Start of enrollment: 2020 Sep 03
- Join now to see all
Publications & Presentations
PubMed
- 395 citationsVenetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trialAndrew H. Wei, Pau Montesinos, VV Ivanov, Courtney D. DiNardo, Jan Novák
Blood. 2020-06-11 - 1097 citationsIbrutinib as initial therapy for patients with chronic lymphocytic leukemiaJan A. Burger, Alessandra Tedeschi, Paul M. Barr, Tadeusz Robak, Carolyn Owen
The New England Journal of Medicine. 2015-12-16 - 162 citationsPembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trialSaad Z. Usmani, Fredrik Schjesvold, Albert Oriol, Lionel Karlin, Michele Cavo
The Lancet. Haematology. 2019-09-01
Press Mentions
Tuesday, Dec 7 2021December 7th, 2021- News Roundup: Vermont Dept. Of Health Reports 78 New COVID-19 CasesApril 22nd, 2021
- UVM Medical Center Pushing Forward with AstraZeneca COVID-19 Vaccine TrialMarch 15th, 2021
- Join now to see all
Professional Memberships
- Member
